 |
市場調査レポート
商品コード
1320065
肺動脈性肺高血圧症の薬剤クラス別市場、流通-世界予測2023-2030年Pulmonary Arterial Hypertension Market by Drug Class, Distribution - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
| 肺動脈性肺高血圧症の薬剤クラス別市場、流通-世界予測2023-2030年 |
|
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 189 Pages
納期: 即日から翌営業日
|
- 全表示
- 概要
- 図表
- 目次
肺動脈性肺高血圧症の薬剤クラス別の世界市場は、2023年に90億8,687万米ドル、CAGR 6.57%で大きく成長し、2030年には142億970万米ドルに達すると予測されています。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは世界の肺動脈性肺高血圧症の薬剤クラス別市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。
市場シェア分析
市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。
本レポートは、以下のポイントに関する洞察を提供します：
1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。
2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。
3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。
4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。
5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。
6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。
本レポートは、以下のような質問にお答えします：
1.肺動脈性肺高血圧症の薬剤クラス別の世界市場規模および予測は？
2.予測期間中、世界の肺動脈性肺高血圧症の薬剤クラス別市場を形成するCOVID-19の阻害要因と影響は？
3.肺動脈性肺高血圧症の薬剤クラス別の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？
4.肺動脈性肺高血圧症の薬剤クラス別の世界市場における競争戦略は？
5.肺動脈性肺高血圧症の薬剤クラス別の世界市場における技術動向と規制の枠組みは？
6.肺動脈性肺高血圧症の薬剤クラス別の世界市場における主要ベンダーの市場シェアは？
7.肺動脈性肺高血圧症の薬剤クラス別の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？
目次
第1章 序文
第2章 調査手法
第3章 エグゼクティブサマリー
第4章 市場の概要
第5章 市場洞察
- 市場力学
- 促進要因
- 心血管疾患の有病率の上昇と高齢者人口の増加
- 希少疾病用医薬品の開発に対する政府の支援的取り組み
- 肺治療用の臨床薬が開発中
- 抑制要因
- 患者の間で肺動脈性肺高血圧症の薬剤クラス別の存在についての認識が限定的
- 肺疾患の診断と治療費は高額
- 機会
- 肺動脈性肺高血圧症の薬剤クラス別の高度な経口薬
- バイオメーカーや新たな遺伝子治療などの治療技術の進歩
- 課題
- 医薬品の臨床承認の複雑なプロセス
- 促進要因
- 市場動向
- COVID-19の累積的な影響
- ロシア・ウクライナ紛争の累積的影響
- 高インフレの累積的影響
- ポーターのファイブフォース分析
- バリューチェーンとクリティカルパス分析
- 規制の枠組み
- 顧客のカスタマイズ
第6章 肺動脈性肺高血圧症の薬剤クラス別市場薬物クラス別
- カルシウムチャネルブロッカー
- エンドセリン受容体拮抗薬
- ホスホジエステラーゼ5
- プロスタサイクリンおよびプロスタサイクリン類似体
第7章 肺動脈性肺高血圧症の薬剤クラス別市場配信別
- 病院薬局
- オンライン薬局
- 小売薬局
第8章 南北アメリカの肺動脈性肺高血圧症の薬剤クラス別市場
- アルゼンチン
- ブラジル
- カナダ
- メキシコ
- 米国
第9章 アジア太平洋地域の肺動脈性肺高血圧症の薬剤クラス別市場
- オーストラリア
- 中国
- インド
- インドネシア
- 日本
- マレーシア
- フィリピン
- シンガポール
- 韓国
- 台湾
- タイ
- ベトナム
第10章 欧州・中東・アフリカの肺動脈性肺高血圧症の薬剤クラス別市場
- デンマーク
- エジプト
- フィンランド
- フランス
- ドイツ
- イスラエル
- イタリア
- オランダ
- ナイジェリア
- ノルウェー
- ポーランド
- カタール
- ロシア
- サウジアラビア
- 南アフリカ
- スペイン
- スウェーデン
- スイス
- トルコ
- アラブ首長国連邦
- 英国
第11章 競合情勢
- FPNVポジショニングマトリクス
- 市場シェア分析：主要企業別
- 競合シナリオ分析：主要企業別
第12章 掲載企業一覧
第13章 付録
- ディスカッションガイド
- ライセンスと価格について
LIST OF FIGURES
- FIGURE 1. PULMONARY ARTERIAL HYPERTENSION MARKET RESEARCH PROCESS
- FIGURE 2. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2022 VS 2030
- FIGURE 3. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
- FIGURE 5. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
- FIGURE 6. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2022 VS 2030 (%)
- FIGURE 7. PULMONARY ARTERIAL HYPERTENSION MARKET DYNAMICS
- FIGURE 8. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 9. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 10. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 11. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 12. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 13. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 14. PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2022
- FIGURE 15. PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2022
LIST OF TABLES
- TABLE 1. PULMONARY ARTERIAL HYPERTENSION MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
- TABLE 3. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 5. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2030 (USD MILLION)
- TABLE 6. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 7. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, BY REGION, 2018-2030 (USD MILLION)
- TABLE 8. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 10. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 14. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 15. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 16. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 17. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 18. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 19. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 20. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 21. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 22. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 23. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 24. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 25. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 26. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 27. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 28. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 29. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 30. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 31. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 32. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 33. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 34. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 35. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 36. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 37. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 38. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 39. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 40. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 41. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 42. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 43. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 44. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 45. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 46. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 47. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 48. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 49. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 50. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 51. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 52. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 53. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 54. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 55. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 56. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 57. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 58. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 59. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 60. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 61. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 62. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 63. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 64. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 65. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 66. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 67. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 68. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 69. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 70. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 71. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 72. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 73. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 74. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 75. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 76. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 77. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 78. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 79. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 80. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 81. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 82. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 83. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 84. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 85. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 86. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 87. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 88. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 89. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 90. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 91. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 92. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 93. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 94. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 95. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 96. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 97. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 98. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
- TABLE 99. PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2022
- TABLE 100. PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2022
- TABLE 101. PULMONARY ARTERIAL HYPERTENSION MARKET LICENSE & PRICING
The Global Pulmonary Arterial Hypertension Market is forecasted to grow significantly, with a projected USD 9,086.87 million in 2023 at a CAGR of 6.57% and expected to reach a staggering USD 14,209.70 million by 2030.
The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Pulmonary Arterial Hypertension Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.
Market Segmentation & Coverage:
This research report categorizes the Global Pulmonary Arterial Hypertension Market in order to forecast the revenues and analyze trends in each of following sub-markets:
Based on Drug Class, market is studied across Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5, and Prostacyclin & Prostacyclin Analog. The Prostacyclin & Prostacyclin Analog is projected to witness significant market share during forecast period.
Based on Distribution, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy is projected to witness significant market share during forecast period.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is essential for assessing the Global Pulmonary Arterial Hypertension Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).
Market Share Analysis:
The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Pulmonary Arterial Hypertension Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pulmonary Arterial Hypertension Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pulmonary Arterial Hypertension Market?
4. What is the competitive strategic window for opportunities in the Global Pulmonary Arterial Hypertension Market?
5. What are the technology trends and regulatory frameworks in the Global Pulmonary Arterial Hypertension Market?
6. What is the market share of the leading vendors in the Global Pulmonary Arterial Hypertension Market?
7. What modes and strategic moves are considered suitable for entering the Global Pulmonary Arterial Hypertension Market?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
- 4.1. Introduction
- 4.2. Pulmonary Arterial Hypertension Market, by Drug Class, 2022 vs 2030
- 4.3. Pulmonary Arterial Hypertension Market, by Distribution, 2022 vs 2030
- 4.4. Pulmonary Arterial Hypertension Market, by Region, 2022 vs 2030
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of cardiovascular diseases and the growing geriatric population
- 5.1.1.2. Supportive government initiatives for the development of orphan drugs
- 5.1.1.3. Clinical drugs in pipeline for pulmonary treatment
- 5.1.2. Restraints
- 5.1.2.1. Limited awareness about presence of pulmonary arterial hypertension among patients
- 5.1.2.2. High diagnosis & treatment cost of pulmonary disorders
- 5.1.3. Opportunities
- 5.1.3.1. Advance oral drugs for pulmonary arterial hypertension
- 5.1.3.2. Technology advancement such as biomaker and new gene therapy for the treatment
- 5.1.4. Challenges
- 5.1.4.1. Complicated process of clinical approval of drugs
- 5.1.1. Drivers
- 5.2. Market Trends
- 5.3. Cumulative Impact of COVID-19
- 5.4. Cumulative Impact of Russia-Ukraine Conflict
- 5.5. Cumulative Impact of High Inflation
- 5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
- 5.7. Value Chain & Critical Path Analysis
- 5.8. Regulatory Framework
- 5.9. Client Customization
6. Pulmonary Arterial Hypertension Market, by Drug Class
- 6.1. Introduction
- 6.2. Calcium Channel Blocker
- 6.3. Endothelin Receptor Antagonists
- 6.4. Phosphodiesterase 5
- 6.5. Prostacyclin & Prostacyclin Analog
7. Pulmonary Arterial Hypertension Market, by Distribution
- 7.1. Introduction
- 7.2. Hospital Pharmacy
- 7.3. Online Pharmacy
- 7.4. Retail Pharmacy
8. Americas Pulmonary Arterial Hypertension Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
9. Asia-Pacific Pulmonary Arterial Hypertension Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
10. Europe, Middle East & Africa Pulmonary Arterial Hypertension Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
12. List of Company Mentioned
13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
